Your browser doesn't support javascript.
loading
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Jackson, Graham H; Davies, Faith E; Pawlyn, Charlotte; Cairns, David A; Striha, Alina; Collett, Corinne; Waterhouse, Anna; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Wilson, Jamie N; Jenner, Matthew W; Cook, Gordon; Kaiser, Martin F; Drayson, Mark T; Owen, Roger G; Russell, Nigel H; Gregory, Walter M; Morgan, Gareth J.
Affiliation
  • Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. Electronic address: graham.jackson@newcastle.ac.uk.
  • Davies FE; Perlmutter Cancer Center, NY Langone Health, New York, NY, USA.
  • Pawlyn C; The Institute of Cancer Research, London, UK; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Cairns DA; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Striha A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Collett C; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Waterhouse A; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Jones JR; The Institute of Cancer Research, London, UK; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Kishore B; Heart of England NHS Foundation Trust, Birmingham, UK.
  • Garg M; Leicester Royal Infirmary, Leicester, UK.
  • Williams CD; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
  • Karunanithi K; University Hospital of North Midlands, Stoke-on-Trent, UK.
  • Lindsay J; East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.
  • Wilson JN; Western Sussex Hospitals NHS Foundation Trust, Chichester, UK.
  • Jenner MW; University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Cook G; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK; Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
  • Kaiser MF; The Institute of Cancer Research, London, UK; The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Drayson MT; Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Owen RG; Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
  • Russell NH; Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, UK.
  • Gregory WM; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
  • Morgan GJ; Perlmutter Cancer Center, NY Langone Health, New York, NY, USA.
Lancet Haematol ; 6(12): e616-e629, 2019 Dec.
Article in En | MEDLINE | ID: mdl-31624047
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Cyclophosphamide / Bortezomib / Multiple Myeloma Type of study: Clinical_trials / Diagnostic_studies / Guideline Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Lancet Haematol Year: 2019 Document type: Article Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dexamethasone / Antineoplastic Combined Chemotherapy Protocols / Cyclophosphamide / Bortezomib / Multiple Myeloma Type of study: Clinical_trials / Diagnostic_studies / Guideline Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Journal: Lancet Haematol Year: 2019 Document type: Article Country of publication: Reino Unido